Webinar

The first Joint Clinical Assessment is here: What market access teams should learn now

The first Joint Clinical Assessment (JCA) offers one of the earliest practical views into how the European Health Technology Assessment Regulation (HTAR) may work in practice — and what that could mean for evidence planning, market access strategy, and launch readiness across Europe.

Key highlights

In this webinar, "Understanding the first JCAs: Practical takeaways for key stakeholders," Cencora and ISPOR, The Professional Society for Health Economics and Outcomes Research explore early lessons from the first JCA assessment and what they may signal for pharmaceutical companies preparing future submissions. The discussion looks beyond process readiness to a more pressing question: whether evidence packages are robust enough to withstand both European Union-level and national-level scrutiny.

Topics include the growing importance of comparative evidence, the risks associated with evidence gaps across multiple PICOs, and the commercial implications of public assessment outcomes that may influence downstream national decisions. Speakers also examine how cross-functional teams may need to adapt their operating models to support earlier evidence planning, stronger indirect comparison strategies, and more proactive management of uncertainty.

Watch the on-demand recording to hear practical takeaways for market access and health economics and outcomes research teams navigating the evolving EU HTA landscape.

Access the webinar recording to learn more

Pardot Form

Siamo qui per aiutarti

Contatta il nostro team oggi stesso per saperne di più su come Cencora sta contribuendo a plasmare il futuro dell'assistenza sanitaria.

Risorse correlate

Guida

La guida essenziale alla commercializzazione dei farmaci

Webinar

Il potenziale trasformativo dell'IA nell'HEOR e nell'accesso al mercato

Articolo

Proiezioni pericolose: In che modo scelte sbagliate di modelli di sopravvivenza con dati immaturi possono fuorviare le decisioni di HTA e avere un impatto sui pazienti